GGrantIndex
Sort

39,280 grants matching leukemia

EZH2 in cancer biology and novel inhibitors

$536,827
Jun Qi · Dana-Farber Cancer Inst · R01 · FY2021 · CA

A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes

$536,812
Qisheng Zhang · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA

JAK Inhibition in Down Syndrome

$536,728
Joaquin M. Espinosa · University Of Colorado Denver · R33 · FY2023 · AR

LEARNING IMPAIRMENTS AMONG SURVIVORS OF CHILDHOOD CANCER

$536,727
St. Jude Children'S Research Hospital · R01 · FY2000 · CA

Targeted Therapy for Lymphoid Malignancies

$536,708
John C Byrd · Ohio State University · R01 · FY2015 · CA

Targeted Therapy for Lymphoid Malignancies

$536,708
John C Byrd · Ohio State University · R01 · FY2016 · CA

Targeted Therapy for Lymphoid Malignancies

$536,708
John C Byrd · Ohio State University · R01 · FY2017 · CA

Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED)-CCC

$536,596
Francis X McCormack · University Of Cincinnati · U01 · FY2021 · HL

Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies

$536,570
John C Byrd · Ohio State University · R01 · FY2016 · CA

Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect

$536,535
Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2017 · CA

Protein Aggregation in Hematopoietic Stem Cells

$536,468
Robert A.j. Signer · University Of California, San Diego · R01 · FY2025 · HL

The Role of PHF6 in HSC self-renewal and myeloid expansion

$536,436
Vikram R. Paralkar · University Of Pennsylvania · R01 · FY2021 · HL

MLL FUSION GENES IN MYELOID AND LYMPHOID LEUKEMIAS

$536,418
Scott A Armstrong · Dana-Farber Cancer Inst · P01 · FY2010 · CA

Novel Regulation of Oncogenic NRAS Signaling in Myeloid Malignancies

$536,367
Wei Tong · Children'S Hosp Of Philadelphia · R01 · FY2023 · CA

Immunology And Pathology Of Acute and Chronic Murine Leukemia Virus Infections

$536,357
Kim Hasenkrug · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Project 4: Transcriptional Coactivators and Enhancers in Human Cancer

$536,356
Christopher Vakoc · Cold Spring Harbor Laboratory · P01 · FY2019 · CA

Targeting cancer stem cells in JAK2V617F induced neoplasm

$536,307
Shaoguang Li · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA

Targeting cancer stem cells in JAK2V617F induced neoplasm

$536,307
Shaoguang Li · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · CA

Behavioral Science Core

$536,191
Alan S Wayne · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA

Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

$536,090
Omar Abdel-Wahab · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Glia maturation factor-gamma modulation of signaling pathways in macrophages

$535,837
Griffin Rodgers · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL

PolQ as a novel therapeutic target in AML

$535,835
Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2022 · CA

TCR engineered T cell therapies for hematologic malignancies

$535,786
Kazusa Ishii · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Cyclin Dependent Kinases as Epigenetic Therapy Targets

$535,736
Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2025 · CA

Escape from CAR T surveillance through lineage plasticity

$535,637
Patricia A Ernst · University Of Colorado Denver · R01 · FY2024 · CA